Loading ETF profile…
The State Street SPDR S&P Pharmaceuticals ETF aims to deliver investment results that closely correspond to the total return of the S&P Pharmaceuticals Select Industry Index, prior to accounting for fees and expenses. It offers investors focused access to the pharmaceuticals segment, specifically the Pharmaceuticals sub-industry as classified by the S&P Total Market Index. By tracking a modified equal-weighted index, the fund ensures a balanced industry exposure across companies of various sizes, including large, mid, and small-cap stocks, thereby mitigating concentration risk. This design provides a more granular approach, empowering investors to adopt strategic or tactical positions within the pharmaceutical sector with greater specificity than traditional, broader sector-based investment vehicles.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| DFTX | DEFINIUM THERAPEUTICS INC | 3.06% | $12.30M |
| MBX | MBX BIOSCIENCES INC | 2.66% | $10.67M |
| ATAI | ATAIBECKLEY INC | 2.17% | $8.71M |
| TRVI | TREVI THERAPEUTICS INC | 2.12% | $8.54M |
| AMLX | AMYLYX PHARMACEUTICALS INC | 2.12% | $8.53M |
| ELVN | ENLIVEN THERAPEUTICS INC | 2.10% | $8.44M |
| ALMS | ALUMIS INC | 2.07% | $8.31M |
| MANE | VERADERMICS INC | 2.03% | $8.16M |
| LGND | LIGAND PHARMACEUTICALS | 1.93% | $7.77M |
| EWTX | EDGEWISE THERAPEUTICS INC | 1.90% | $7.63M |
| NUVB | NUVATION BIO INC | 1.87% | $7.52M |
| MAZE | MAZE THERAPEUTICS INC | 1.80% | $7.24M |
| NKTR | NEKTAR THERAPEUTICS | 1.76% | $7.07M |
| LQDA | LIQUIDIA CORP | 1.76% | $7.07M |
| HROW | HARROW INC | 1.75% | $7.04M |
| EYPT | EYEPOINT INC | 1.75% | $7.03M |
| OCUL | OCULAR THERAPEUTIX INC | 1.73% | $6.96M |
| AMRX | AMNEAL PHARMACEUTICALS INC | 1.72% | $6.93M |
| CORT | CORCEPT THERAPEUTICS INC | 1.72% | $6.91M |
| MRK | MERCK + CO. INC. | 1.66% | $6.67M |
| JNJ | JOHNSON + JOHNSON | 1.66% | $6.66M |
| INDV | INDIVIOR PHARMACEUTICALS INC | 1.66% | $6.65M |
| LLY | ELI LILLY + CO | 1.65% | $6.65M |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.65% | $6.64M |
| CRNX | CRINETICS PHARMACEUTICALS IN | 1.64% | $6.61M |